Tateishi, K <br/><br/>
The immunosuppressant FK506 promotes development of the chondrogenic phenotype in human synovial stromal cells via modulation of the Smad signaling pathway.  [electronic resource] 

 -  Osteoarthritis and cartilage  Jun 2007 
 - 709-18 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1063-4584 
<br/><br/><label>Standard No.: </label>10.1016/j.joca.2007.01.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Cartilage, Articular--drug effects<br/>Chondrocytes--drug effects<br/>Chondrogenesis--drug effects<br/>Female<br/>Gene Expression Regulation--drug effects<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Male<br/>Middle Aged<br/>Phenotype<br/>Signal Transduction--drug effects<br/>Smad Proteins--drug effects<br/>Stromal Cells--drug effects<br/>Tacrolimus--therapeutic use<br/>Transforming Growth Factor beta1--drug effects